biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Jun 28, 2016 10:44am

102 Views

Post# 25004616

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Update

Good news? Based on what? Stock reaction, value change in the company, or simply just another subjective prespective?

Yes Yes, quite correct, it's my subjective perspective.

Examples of good news stories are Scarpa & MPS II, delivery of siRNA, development of MTfp, and Texas Tech & Herceptin. All important to moving the process along but not reflected in the stock price.

The fact that you admit that the market has not provided any value to "many good news stories" should tell you the value of these "good news stories."

Maybe, maybe not.

If we had the data to get a "money deal" then this would not be priced where it is. I'm not sure why you are having a difficult time grasping this.

I got chased by a dog one time when I was out biking. I ended up going over the handle bars into a bunch of trees. Woke up on the ground some time later. Got hit in the head pretty good I think.

We aren't privy to all the studies/data. Some are public, others are done at the pharmas and not released.

Anyhow, it's just a difference of opinion. That's OK. That's what makes a market. I have no need to convince you of anything. Maybe you're right, maybe not.

If you don't mind, I'll just add that last paragraph to your list of predictions....

2016-06-28
If we had the data to get a "money deal" then this would not be priced where it is. I'm not sure why you are having a difficult time grasping this. I guess you can only lead a horse to the water and not push its head in it.

2016-06-24
I think if they get any "deals" where there is revenue upfront then it may move a bit, but those upfront fees will be minimal and may take this to 2 or 3.

2016-06-22
I don't see Bioasis making any meaningful move in pps until we have some clinical, human, data.

2016-06-22
No one is sold on the "technology" otherwise the IP you talk of would be gone instead of having "so many" pharmas "working" with Bioasis.

2016-06-21
6 down and 6 more to go...until you will be gone when this will be about right where it is now.

2016-06-13
I believe nothing will happen this year. Just like all the prior years.

Bullboard Posts

How one company is disrupting PoC testing